EP Patent

EP0860433B1 — Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same

Assigned to Kirin Brewery Co Ltd · Expires 2002-07-03 · 24y expired

What this patent protects

Novel quinoline derivatives and quinazoline derivatives represented by general formula (I) which have an inhibitory effect on the autophosphorylation of growth factor receptors originating in platelets and pharmaceutically acceptable salts thereof; pharmaceutical compositions con…

USPTO Abstract

Novel quinoline derivatives and quinazoline derivatives represented by general formula (I) which have an inhibitory effect on the autophosphorylation of growth factor receptors originating in platelets and pharmaceutically acceptable salts thereof; pharmaceutical compositions containing these compounds; and a method for treating diseases relating to the abnormal proliferation of cells such as the proliferation of tumors, wherein R1 and R2 represent each H or C1-4 alkyl, or R1 and R2 together form C1-3 alkylene; X represents O, S or CH2; W represents CH or N; and Q represents substituted aryl or substituted heteroaryl.

Drugs covered by this patent

Patent Metadata

Patent number
EP0860433B1
Jurisdiction
EP
Classification
Expires
2002-07-03
Drug substance claim
No
Drug product claim
No
Assignee
Kirin Brewery Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.